[1]
Van Noesel MM, Versteeg R. Pediatric neuroblastomas: Genetic and epigenetic ‘danse macabre’. Gene 2004; 325: 1-15.
[5]
Kushner BH, Gilbert F, Helson L. Familial neuroblastoma: Case reports, literature review, and etiologic considerations. Cancer 1986; 57: 1887.
[6]
Hallett A, Traunecker H. A review and update on neuroblastoma J Pediatr Child Health. 2012; 22(22): 103.
[14]
Richards RM, Sotillo E, Majzner RG. CAR T cell therapy for neuroblastoma. Frontiers in Immunology 2018; 9: 2380.
[17]
Imbach P. Neuroblastoma.Pediatric Oncology, A comprehensive Guide New York: Springer –Verlag Berlin Heidelberg Publications. 2004; pp. 119-28.
[19]
Kesrouani A, Duchatel F, Seilanian M, Muray JM. Prenatal Diagnosis of Adrenal Neuroblastoma by Ultrasound: A Report of Two Cases and Review of the Literature 1999.
[23]
Schilling FH, Bihl H, Jacobsson H, Ambros PF, Martinsson T, Borgström P, et al. al. Combined (111) In-pentetreotide scintigraphy and (123) I-mIBG scintigraphy in neuroblastoma provides prognostic information. Med Pediatr Oncol 2000; 35: 688-91.
[27]
Morgenstern DA, London WB, Stephens D, Volchenboum SL, Simon T, Nakagawara A, et al. Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. Eur J Cancer 2016.
[28]
Colon NC, Chung DH. Neuroblastoma. Adv Pediatr 2011; 58: 279-311.
[32]
Perakis S, Speicher MR. Emerging concepts in liquid biopsies. 2017; 15: 75.
[39]
Wu YH, Song B, Xu J, Chen WX, Zhao WX, Jia R, et al. Retroperitoneal neoplasms within the perirenal space in infants and children: differentiation of renal and non-renal origin in enhanced CT images. Eur J Radiol 2010; 75(3)
[41]
Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL. MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med 2009; 50: 1237.
[42]
Albers AR, O’Dorisio MS, Balster DA, Caprara M, Gosh P, Chen F, et al. Somatostatin receptor gene expression in neuroblastoma. Regul Pept 2000; 88: 61-73.
[43]
Brodeur GM, Seeger RC, Schwab M, Vamus HE, Bishop JM. Amplification of NMYC gene in untreated human Neuroblastoma correlated with advanced disease stage. Science 224: 1121-4.
[44]
Molenaar JJ, Koster J, Zwijnenburg DA, Sluis PV, Valentijn LJ, van der Ploeg I, et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 2012; 483-593.
[50]
Duijkers FAM, Gaal J, Meijerink JP, et al. High anaplastic lymphoma kinase immunohistochemical staining in neuroblastoma and ganglioneuroblastoma is an independent predictor of poor outcome. Am J Pathol 2012; 180(3): 1223-31.
[51]
Bielle F, Fréneaux P, Jeanne-Pasquier C, Maran-Gonzalez A, Rousseau A, Lamant L, et al. PHOX2B immunolabeling: A novel tool for the diagnosis of undifferentiated neuroblastomas among childhood small round blue-cell tumors. Am J Surg Pathol 2012; 36: 1141-9.
[57]
Lu D, Liu J, Chen Y, Chen F, Yang H. Primary Cervical Ganglioneuroblastoma: A Case Report. Medicine (Baltimore 2018; 97(12)
[61]
SEER1 Cancer Statistics Review. National Cancer Institute, Surveillance, Epidemiology and End result program 1999.
[71]
Von Schweinitz D, Hero B, Berthold F. The impact of surgical radicality on outcome in childhood neuroblastoma. Eur J Pediatr Surg 2002; 6: 402-9.
[72]
Luo YB, Cui XC, Yang L, Zhang D, Wang JX. Advances in the Surgical Treatment of Neuroblastoma. Chin Med J 2018.
[76]
Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, et al. Al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A Children’s oncology group study. J Clin Oncol 2009; 27(7): 1007-3.
[77]
Ladenstein R, Pötschger U, Hartman O, Pearson ADJ, Klingebiel T, Castel V, et al. years of high-dose therapy and SCT for neuroblastoma in Europe: Lessons from more than 4000 procedures. Bone Marrow Transplant 2008.
[80]
Ladenstein R, Pötschger U, Pearson ADJ, Brock P, Luksch R, Castel V, et al. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): An international, randomized, multi-arm, open-label, phase 3 trial. Lancet Oncol 2017; 18(4): 500-14.
[82]
Simon T, Bongartz R, Hero B, Schmidt M, Müller RP, Berthold F. Intensified external beam radiation therapy improves the outcome of stage 4 neuroblastoma in children >1 year with residual local disease. Strahlenther Onkol 2006; 182(7): 389-94.
[84]
Modak S, Cheung NK. Neuroblastoma: Therapeutic strategies for a clinical enigma. Cancer Treat Rev Jun 36(4): 307-17.
[86]
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours. European J Cancer 2009; 45(2): 228-47.
[88]
Wang X, Wang L, Su Y, Yue Z, T, Zhao W, Zhao Q, et al. Plasma cell free DNA quantification is highly correlated with tumor burden in children with neuroblastoma. Cancer Med 2018; 7: 3022-30.
[89]
Cole KA, Maris JM. New Strategies in Refractory and Recurrent Neuroblastoma: Translational Opportunities to Impact Patient Outcome. Clin Cancer Res 2012; 18: 2423-8.
[92]
London WB, Bagatell R, Weigel BJ, et al. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children’s Oncology Group early-phase trials. Cancer 2017; 123: 4914-23.
[97]
Kushner BH, Ostrovnaya I, Cheung IY, et al. Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with anti-GD2 immunotherapy and isotretinoin: A prospective phase II study. Oncoimmunology 2015; 4
[98]
London WB2, Frantz CN, Campbell LA, Seeger RC, Brumback BA, Cohn SL. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: A children’s oncology group study. J Clin Oncol 2010; 28: 3808-15.
[100]
Kushner BH, Kramer K, Modak S, Qin LX, Cheung NKV. Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma. Cancer 2010; 116: 3045-60.
[102]
Modak S, Kushner BH, Basu E, Roberts SS, Cheung NKV. Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study. Pediatr Blood Cancer 2017; 64
[116]
Hartmann O, Valteau-Couanet D, Vassal G, Lapierre V, Brugières L, Delgado R, et al. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: A multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant 1999.
[133]
Schmidt M, Simon T, Hero B, Dietlein M, Sudbrock F, Bongartz R, et al. Is there a benefit of 131I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of the German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004. Nucl Med (Stuttg) 45(4): 145-51. [PMID: 16964339].
[136]
Mastrangelo R, Tornesello A, Riccardi R, et al. A new approach in the treatment of stage IV neuroblastoma using a combination of I131 meta-iodobenzylguanidine (MIBG) and cisplatin European Journal of Cancer 1995; 31(4): 606-11.
[139]
Rybak L, Mukherjea D, Jajoo S, Ramkumar V. Cisplatin ototoxicity and protection: Clinical and experimental studies. Tohoku J Exp Med 2009; 219(3): 177-86.
[146]
Abbas AA, Khalid KA. Chronic persistent neuroblastoma. A unique presentation and clinical course in a six-year-old child. A case report. Clin in Oncol J 2019; 4(1677): 1-6.